DHR vs LLY
DHR: A diversified conglomerate applying advanced technologies and quality manufacturing across life sciences, diagnostics, environmental & applied solutions, and industrial products. LLY: A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss franchises driving exceptional growth.
Side-by-side fundamentals
| Metric | DHR | LLY | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $195.98 | $1,216.95 | |
| Market cap as of 2026-07-10 | $137.8B | $1.15T | |
| P/E as of 2026-07-10 | 37.35 | 45.52 | DHR lower |
| PEG as of 2026-07-10 | 3.97 | 1.37 | LLY lower |
| Net margin as of 2026-07-10 | +14.9% | +35.0% | LLY higher |
| Gross margin as of 2026-07-10 | +59.0% | +82.8% | LLY higher |
| Operating margin as of 2026-07-10 | +19.2% | +43.6% | LLY higher |
| ROE as of 2026-07-10 | +7.1% | +101.3% | LLY higher |
| ROA as of 2026-07-10 | +4.5% | +22.7% | LLY higher |
| Debt / equity as of 2026-07-10 | 0.35 | 1.39 | DHR lower |
| Revenue growth (YoY) as of 2026-07-10 | +4.0% | +47.4% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | +31.7% | LLY higher |
| Dividend yield as of 2026-07-10 | +0.8% | +0.6% | DHR higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-10 | 0.78 | 0.50 | |
| 1-year return as of 2026-07-09 close | -4.9% | +54.6% | LLY higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.